Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A surprisingly early distribution and a stretched valuation hit J&J's consumer health arm hard.

Johnson & Johnson Rips Off the Kenvue Band-Aid

Johnson & Johnson beat quarterly expectations Thursday, helped by its new cancer drug Carvykti, and JNJ stock surged.

J&J Stock Roars Higher, Retaking Its 200-Day Line As Small Drugs Drive Big Beat

After three years of waiting, Johnson & Johnson NYSE: JNJ shares have returned to trend, a monumental event for the market which presents a potential buying opportunity for income investors.

Johnson & Johnson's Inflection Point: What it Means for Investors

American Airlines

Both J&J and American Airlines put up solid beats on top and bottom lines, while the labor market remains buoyant.

Q2 Beats for J&J, American; Jobless Claims, Philly Fed Lower

Johnson & Johnson (NYSE: JNJ) opened 5.0% up on Thursday after reporting market-beating results for its fiscal second quarter. J&J stock up on strong outlook Investors are cheering the raised guidance as well.

J&J raises full-year outlook: ‘we're in a very strong position'

The healthcare giant posted better-than-expected 2023 Q2 financial results today.

Why Johnson & Johnson Stock Is Rising Today

Target

Dividend stocks often provide an important source of income for retirees. Target and Johnson & Johnson are two top-shelf dividend stocks suitable for risk-averse investors.

2 Ultra-Safe Dividend Stocks Retirees May Want to Consider Buying

Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Johnson & Johnson (JNJ) Q2 Earnings

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.59 per share a year ago.

Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates

Net earnings at the pharmaceutical company rose 6.9% to $5.14 billion, or $1.96 a share.

J&J Revenue Up on Surge in Heart Procedures

Johnson & Johnson (NYSE:JNJ) has delivered second-quarter earnings that beat expectations and has raised its full-year guidance, sending its shares higher in Thursday pre-marketing trading.  The company reported a 6.3% rise in sales to $25.5 billion for the three months to June 30, 2023.

Johnson & Johnson reports 2Q earnings beat and raises guidance

Johnson & Johnson's stock JNJ, -0.20% rose 2.4% in premarket trade Thursday, after the health care company posted better-than-expected second-quarter earnings and raised its guidance. The company posted net income of $5.144 billion, or $1.96 a share, for the quarter, up from $4.814 billion, or $1.80 a share, in the year-earlier period.

Johnson & Johnson's stock up 2.4% premarket after earnings top estimates and company raises guidance

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2023 of $1.19 per share on the company's common stock. The dividend is payable on September 7, 2023 to shareholders of record at the close of business on August 28, 2023. The ex-dividend date is August 25, 2023. About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communi.

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2023

The results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.

Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge

Johnson & Johnson raised its 2023 profit forecast on Thursday, banking on the strength in its medical devices business and demand for its cancer drugs such as Darzalex.

J&J raises annual profit forecast on medical devices, cancer drugs strength

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmac.

Johnson & Johnson Reports Q2 2023 Results

Jury rules in favor of California man who says he developed a deadly cancer from heavy exposure to talc powder since childhood

Johnson & Johnson must pay $18.8m to cancer patient in baby powder lawsuit

Johnson & Johnson must pay $18.8 million to a California man who said he developed cancer from exposure to its baby powder, a jury decided on Tuesday, a setback for the company as it seeks to settle thousands of similar cases over its talc-based products in US bankruptcy court.

Johnson & Johnson must pay $18.8 million to California cancer patient in baby powder suit

Johnson & Johnson's must pay $18.8 million to a California man who said he developed cancer from exposure to its baby powder, a jury decided on Tuesday, a setback for the company as it seeks to settle thousands of similar cases over its talc-based products in U.S. bankruptcy court.

J&J must pay $18.8 mln to California cancer patient in baby powder suit

Merck

Johnson & Johnson JNJ, -0.01% has joined companies such as Merck & Co. Inc. MRK, +0.36%, Bristol Myers Squibb Co. BMY, +0.24% and other entities in suing the federal government over Medicare's drug-price negotiation program. Merck was first with its suit in June, alleging that the plan is a scheme to allow Medicare to obtain prescription drugs without paying fair market value, a contention the Biden administration has decried.

Johnson & Johnson joins Merck, others, in fighting Medicare drug-price program

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.

J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector

Johnson & Johnson sued the U.S. government on Tuesday, becoming the latest drugmaker seeking to block enforcement of a program that gives Medicare the power to negotiate drug prices.

J&J sues US govt to halt Medicare drug price negotiation plans

American Express

Netflix

Earnings season is always an exciting time to be an investor, with companies finally pulling the curtain back and unveiling what's transpired behind closed doors.

3 Quarterly Reports Investors Can't Ignore This Week

LOS ANGELES--(BUSINESS WIRE)-- #COVID19--With Johnson and Johnson (J&J) recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries, AIDS Healthcare Foundation (AHF) applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement. While the deal is a positive step, AHF agrees with advocates, including Médecins Sans Frontières and others,.

J&J-Stop TB Partnership Deal a Positive Step but More Is Needed, says AHF

We expect the company's revenues to come in at $24.6 billion, marginally below the consensus estimate of $24.7 billion.

News for Johnson & Johnson Stock (JNJ)